Prothya Biosolutions: Clinical Trials

11 trials sponsored by Prothya Biosolutions, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 3 terminated, 1 active not recruiting. 11 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 311Completed 7, Terminated 3, Active not recruiting 1
Phase 24Completed 2, Active not recruiting 1, Terminated 1

Follow Prothya Biosolutions: new trials by email

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Add-on Intravenous Immunoglobulins in Early Myositis
Immune Globulin Intravenous (Human), Placebo - Inflammatory Myopathy, Idiopathic, Dermatomyositis
Phase 2 / Phase 3Active not recruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)442021-09-132026-02-27
Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)
ConvP, FFP - Covid19
Phase 3TerminatedErasmus Medical Center4202020-10-122022-04-01
Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)
Convalescent plasma - COVID-19
Phase 2 / Phase 3TerminatedErasmus Medical Center862020-04-082022-04-01
Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml
Intravenous immunoglobulin infusion - Primary Immunodeficiency
Phase 3CompletedProthya Biosolutions232013-12-012015-04-06
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II
C1-esterase inhibitor, Endotoxin - Innate Immune Response, Endotoxemia
Phase 3CompletedRadboud University Medical Center202013-09-012014-12-02
Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture
C1-esterase inhibitor, Saline 0.9% - Trauma, Inflammation
Phase 3TerminatedUMC Utrecht112012-04-012015-02-04
Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy
Intravenous Immunoglobulins, plasma volume expander - Myocardial Diseases, Parvovirus B19, Human
Phase 3CompletedProthya Biosolutions502009-11-012018-08-29
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
C1 inhibitor concentrate (C1-esteraseremmer-N) - Angioedema
Phase 2 / Phase 3CompletedProthya Biosolutions62006-11-012009-05-04
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
C1 inhibitor concentrate (C1-esteraseremmer-N) - Angioedema
Phase 3CompletedProthya Biosolutions152006-02-012009-05-04
Efficacy and Safety of IVIG-L in ITP Patients
IVIG-L - Purpura, Thrombocytopenic, Idiopathic
Phase 3CompletedProthya Biosolutions202001-10-012006-01-31
Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients
IVIG-L - Hypogammaglobulinemia
Phase 2 / Phase 3CompletedProthya Biosolutions152001-05-012007-04-19

Conditions studied

Acquired angioedema (2)  ·  Angioedema (2)  ·  COVID-19 (2)  ·  Hereditary Angioedema Types I and II (2)  ·  Inflammation (2)  ·  Sepsis (2)  ·  Agammaglobulinemia (1)  ·  Angioedemas, Hereditary (1)  ·  Antisynthetase syndrome (1)  ·  Cardiomyopathies (1)  ·  Dermatomyositis (1)  ·  Endotoxemia (1)  ·  Multiple Organ Failure (1)  ·  Myositis (1)  ·  Polymyositis (1)

Interventions

Complement C1 Inhibitor Protein (2)  ·  Immunoglobulins, Intravenous (2)  ·  Sodium Chloride (2)  ·  Endotoxins (1)  ·  Plasma Substitutes (1)  ·  let-363 protein, C elegans (1)

Countries

Netherlands (10)  ·  Poland (1)

Top investigators

Bart Rijnders, MD, PhD (2)  ·  M. M. Levi, Prof. Dr. (2)  ·  F P Kroon, PhD, MD (1)  ·  Hans Hoeven, Prof (1)  ·  Luke P Leenen, MD, PhD (1)  ·  P FW Strengers, MD (1)  ·  S Heymans, PhD, MD (1)

Results publications

PMID 21988742, PMID 28515092, PMID 33044747, PMID 33347677, PMID 34013969, PMID 35546145, PMID 36734509, PMID 37162745